Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
|Articles|September 18, 2020
Supplements and Featured Publications
- Multiple Sclerosis Compendium Newsletter
Multiple Sclerosis Compendium Newsletter
In this newsletter, The American Journal of Managed Care® will present data and key findings from recent clinical studies as well as an interview from key opinion leader, Thomas Leist, MD, PhD.
Advertisement
Advertisement
Related to this article
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
A narrative review finds specialty pharmacies lack a patient-reported outcome measure built for their workflow, despite frequent contact with patients with MS.
Patients with colorectal or ovarian cancer enrolled in a clinical trial have lower pharmacy and medical costs during the 9 months after trial initiation.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
3
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
4
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
5